C. auris is an emerging, deadly, drug-resistant yeast. Some strains are resistant to all three major classes of antifungal drugs, making it of particular concern.
The first domestic cases of C. auris infections in the U.S. were reported in November 2016 and as of April 13, 61 infections have been reported in six states, according to the CDC.
The threat of C. auris should spur officials to attempt to better contain the fungus and other superbugs, according to Dr. Schuchat.”This is a big threat and a wake-up call,” Dr. Schuchat told STAT. “It was a problem for Ebola. It was a problem for SARS. It’s a problem for drug resistance.”
The CDC revised its guidelines to control C. auris in February. See the full recommendation here.
More articles on drug resistance:
Experts: US needs more comprehensive MRSA tracking system
7 things to know about inpatient, outpatient antibiotic use
FDA approves diagnostic tool for antibiotic stewardship
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
